Hyperfine, Inc. (HYPR): Cost of Revenue
$6.81M
Year ended 2025-12-31
$8.04M
Trailing 12 months to 2026-06-30
+4.9%
3-year compound annual growth
+54.6%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.81M | -2.7% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $7.00M | +11.5% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $6.28M | +6.2% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $5.91M | +121.8% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $2.66M | +245.4% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $771.0K | n/a | 2022-03-25, From 2020-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Hyperfine, Inc. (HYPR) | 2025-12-31 | $6.81M | -2.7% |
| CapsoVision, Inc (CV) | 2025-12-31 | $6.38M | +18.6% |
| Escalon Medical Corp (ESMC) | 2025-06-30 | $6.54M | -4.4% |
| QT Imaging Holdings, Inc. (QTI) | 2025-12-31 | $10.34M | +361.9% |
| Precision Optics Corporation, Inc. (POCI) | 2025-06-30 | $15.69M | +17.9% |
| Nuwellis, Inc. (NUWE) | 2025-12-31 | $3.15M | +2.7% |
| electroCore, Inc. (ECOR) | 2025-12-31 | $4.24M | +12.1% |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $15.31M | +24.2% |
| Neuraxis, Inc (NRXS) | 2025-12-31 | $562.9K | +55.5% |
Compare HYPR, CV, ESMC, QTI side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗